Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.94 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | GAA | P10253 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.94 |
| ▸ | BLM | P54132 | 1/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.94 |
| ▸ | TTR | P02766 | 3/20 | 0.73 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.73 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.73 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.73 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.73 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL8765115 | 1.00 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL40784 | 1.00 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL1232980 | 0.98 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL24009 | 0.97 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL1650617 | 0.97 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL1244510 | 0.97 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL29350388 | 0.97 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL27229363 | 0.97 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL21048102 | 0.95 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL6509233 | 0.95 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091011-A1 | HYDROALCOHOLIC SINGLE PHASE GEL COMPOSITIONS FOR TOPICAL DELIVERY OF DICLOFENAC | HALEON CH SARL (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240382597-A1 | FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER | LIVIONEX INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240350401-A1 | TOPICAL DELIVERY SYSTEMS FOR ACTIVE COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-24 | — | — | US | claimed |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2024-03-14 | — | — | US | claimed |
| EP-4304570-A2 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES | Phor-Med, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117015375-A | Compositions and methods for treating Acute Respiratory Distress Syndrome (ARDS) and inflammatory conditions caused by coronaviruses | 福尔医学公司 | 2023-11-07 | — | — | CN | claimed |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | PHOR-MED, INC. | 2023-08-10 | — | — | US | claimed |
| WO-2023129171-A1 | FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER | LIVIONEX, Inc. (US) | 2023-07-06 | — | — | WO | claimed |
| US-20220054440-A1 | SUBSTANTIALLY SODIUM FREE DICLOFENAC POTASSIUM ORAL SOLUTIONS | APPLIED PHARMA RES (CH) | 2022-02-24 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4722725-A2 | COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260091011-A1 | HYDROALCOHOLIC SINGLE PHASE GEL COMPOSITIONS FOR TOPICAL DELIVERY OF DICLOFENAC | HALEON CH SARL (CH) | 2026-04-02 | — | — | US | disclosed |
| US-11260026-B2 | Ready to use diclofenac stick packs | APR APPLIED PHARMA RESEARCH SA (CH) | 2022-03-01 | — | — | US | disclosed |
| WO-2022036453-A1 | TREATMENT METHODS FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS | SERENITY BIOWORKS INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| US-20220054426-A1 | DUAL LANE COATING | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054440-A1 | SUBSTANTIALLY SODIUM FREE DICLOFENAC POTASSIUM ORAL SOLUTIONS | APPLIED PHARMA RES (CH) | 2022-02-24 | — | — | US | disclosed |
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, MAFK, ACP3 | PTGS2 4070/4885PTGS1 3864/4885CYP2C9 4564/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PTGS2 2731/4885PTGS1 3480/4885CYP2C9 1378/4885 |
| US-20240350401-A1 | TOPICAL DELIVERY SYSTEMS FOR ACTIVE COMPOUNDS | VEGFA, MMP10, LIPA | PTGS2 476/4885PTGS1 727/4885CYP2C9 2454/4885 |
| US-20240382597-A1 | FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER | TNF, CD14, CXCL8 | PTGS2 34/4885PTGS1 15/4885CYP2C9 959/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | PTGS2 81/4885PTGS1 97/4885CYP2C9 4129/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | PTGS2 1383/4885PTGS1 1534/4885CYP2C9 3254/4885 |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | MAVS, ACE2, PLAA | PTGS2 45/4885PTGS1 43/4885CYP2C9 4672/4885 |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | MAVS, ACE2, CCL11 | PTGS2 29/4885PTGS1 30/4885CYP2C9 4508/4885 |
| US-20260091011-A1 | HYDROALCOHOLIC SINGLE PHASE GEL COMPOSITIONS FOR TOPICAL DELIVERY OF DICLOFENAC | PTGER3, DGAT2, DGAT1 | PTGS2 75/4885PTGS1 76/4885CYP2C9 316/4885 |
| US-20220054440-A1 | SUBSTANTIALLY SODIUM FREE DICLOFENAC POTASSIUM ORAL SOLUTIONS | KCNN3, KCNN2, KCNN1 | PTGS2 543/4885PTGS1 355/4885CYP2C9 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.